C.R. Bard Subsidiary Wins Injunction Against CyroLife

This week, Medafor, a C.R. Bard subsidiary, won a preliminary injunction barring US sales of CryoLife's PerClot Topical hemostasis agent in a patent infringement lawsuit in the District of Delaware before Judge Sue Robinson. In April 2014, CryoLife filed a declaratory judgment lawsuit for non-infringement of Medafor's US Patent No. 6,060,461. Medafor counterclaimed, and filed a motion for a preliminary injunction against CryoLife in September 2014. [3/13/15]